Therapeutic nucleic acids: current clinical status

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 659-672

  Sridharan, Kannan ^a   Gogtay, Nithya Jaideep ^b  

^a FIJI NATIONAL UNIVERSITY   (Fiji)

^b KEM HOSPITAL   (India)

Author keywords

antisense oligonucleotides; aptamers; gene therapy; ribozymes; RNA decoys

Indexed keywords

ALIPOGENE TIPARVOVEC; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CIRCULAR RNA; DNA; FOMIVIRSEN; GENDICINE; MICRORNA; MIPOMERSEN; MIRAVIRSEN; NUCLEIC ACID; RIBOZYME; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; ARTHRALGIA; CHILL; DRUG TARGETING; FATIGUE; FEVER; GENE THERAPY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MALAISE; MYALGIA; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULOPATHY; REVIEW; RIBOZYME THERAPY; RISK BENEFIT ANALYSIS; RNA INTERFERENCE;

EID: 84982933442     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12987     Document Type: Review

References (112)

1. Breaker RR, Joyce GF. The expanding view of RNA and DNA function. Chem Biol 2014; 21: 1059–65.
2. Khakshoor O, Kool ET. Chemistry of nucleic acids: impacts in multiple fields. Chem Commun 2011; 47: 7018–24.
3. Opalinska JB, Gewirtz AM. Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1: 503–14.
4. Muralidhara BK, Baid R, Bishop SM, Huang M, Wang W, Nema S. Critical considerations for developing nucleic acid macromolecule based drug products. Drug Discov Today 2016; 21: 430–44.
5. Ho D, Wang C-H K, Chow EK-H. Nanodiamonds: the intersection of nanotechnology, drug development and personalized medicine. Sci Adv 2015; 1: e1500439.
6. Wraight CJ, White PJ. Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 2001; 90: 89–104.
7. Cavagnari BM. Gene therapy: nucleic acids as drugs. Action, mechanisms and delivery into the cell. Arch Argent Pediatr 2011; 109: 237–44.
8. Martinez T, Jimenez AI, Paneda C. Short-interference RNAs: becoming medicines. EXCLI J 2015; 14: 714–46.
9. Lucas-Samuel S, Ferry N, Trouvin JH. Overview of the regulatory oversight implemented by the French regulatory authorities for the clinical investigation of gene therapy and cell therapy products. Adv Exp Med Biol 2015; 871: 73–85.
10. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11: 125–40.
11. Andronescu M, Zhang ZC, Condon A. Secondary structure prediction of interacting RNA molecules. J Mol Biol 2005; 345: 987–1001.
12. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: tools for targeted cancer therapy. Mol Ther Nucleic Acids 2014; 3: e182.
13. Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011; 18: 4206–14.
14. Blind M, Blank M. Aptamer selection technology and recent advances. Mol Ther Nucleic Acids 2015; 4: e223.
15. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008; 130: 9137–43.
16. Syed M, Pervaiz S. Advances in sptamers. Oligonucleotides 2010; 20: 215–24.
17. Santosh B, Yadava PK. Nucleic acid aptamers: research tools in disease diagnostics and therapeutics. BioMed Res Int 2014; 2014: 540451.
18. Shum KT, Zhou J, Rossi JJ. Nucleic acid aptamers as potential therapeutic and diagnostic agents for lymphoma. J Cancer Ther 2013; 4: 872–90.
19. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007; 14: 283–91.
20. Chan JHP, Lim S, Wong WSF. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533–40.
21. Stanton R, Sciabola S, Salatto C, Weng Y, Moshinsky D, Little J, et al. Chemical modification study of antisense gapmers. Nucleic Acid Ther 2012; 22: 344–59.
22. Wan WB, Migawa MT, Vasquez G, Murray HM, Nichols JG, Gaus H, et al. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res 2014; 42: 13456–68.
23. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259–93.
24. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009; 5: 381–91.
25. Evers MM, Toonen LJA, van Roon-Mom WMC. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 2015; 87: 90–103.
26. Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 2013; 9: 169–82.
27. Mansoor M, Melendez AJ. Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio 2008; 2: 275–95.
28. Tse MT. Antisense approval provides boost to the field. Drug Discov 2013; 12: 179.
29. Grillone LR, Lanz R. Fomivirsen. Drugs Today (Barc) 2001; 37: 245–55.
30. Wong E, Goldberg T. Mipomersen (Kynamro). A novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. Pharm Therapeut 2014; 39: 119–22.
31. Orr RM. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc./CIBA vision. Curr Opin Mol Ther 2001; 3: 288–94.
32. Henry SP, Miner RC, Drew WL, Fitchett J, York-Defalco C, Rapp LM, et al. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Invest Ophthalmol Vis Sci 2001; 42: 2646–51.
33. Geary RS, Henry SP, Grillone LR. Fomivirsen: clinical pharmacology and potential drug interactions. Clin Pharmacokinet 2002; 41: 255–60.
34. The Vitravene study group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002; 133: 475–83.
35. Vitravene Study Group 2. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133: 484–98.
36. Stone TW, Jaffe GJ. Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for cytomegalovirus retinitis. Am J Ophthalmol 2000; 130: 242–3.
37. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729–35.
38. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: 133–40.
39. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998–1006.
40. McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012; 7: 133–40.
41. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126: 2283–92.
42. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372: 232–40.
43. Thomas M, Ge Q, Lu JJ, Chen J, Klibanov AM. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res 2005; 22: 373–80.
44. Mastrobattista E, Hennink WE, Schiffelers RM. Delivery of nucleic acids. Pharm Res 2007; 24: 1561–3.
45. Kjems J, Howard KA. Oligonucleotide delivery to the lung: waiting to inhale. Mol Ther Nucleic Acids 2012; 1: e1.
46. Nishina T, Numata J, Nishina K, Yoshida-Tanaka K, Nitta K, Piao W, et al. Chimeric antisense oligonucleotide conjugated to alpha-tocopherol. Mol Ther Nucleic Acids 2015; 4: e220.
47. Misra S. Human gene therapy: a brief overview of the genetic revolution. JAPI 2013; 61: 127–33.
48. Papadakis ED, Nicklin SA, Baker AH, White SJ. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 2004; 4: 89–113.
49. Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 2012; 1: 27.
50. Mathews QL, Curiel DT. Gene therapy: human gemline genetics modifications – assessing the scientific, socioethical, and religious issues. South Med J 2007; 100: 98–100.
51. Sibbald B. Death but one unintended consequence of gene therapy trial. CMAJ 2001; 164: 1612.
52. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 – an update. J Gene Med 2013; 15: 65–77.
53. Peng H. Current status of Gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016–27.
54. Krimsky S. China's gene therapy drug. Genewatch 2005; 18: 10–3.
55. Li J, Pan J, Zhu X, Su Y, Bao L, Qiu S, et al. Recombinant adenovirus-p53 (Gencidine) sensitizes a pancreatic carcinoma cell line to radiation. Chin J Can Res 2013; 25: 715–21.
56. Yla-Herttuala S. Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 2012; 20: 1831–2.
57. United States Food and Drug Administration. Guidance for industry. Gene therapy for clinical trials – observing subjects for delayed adverse events. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm078719.pdf (last accessed 22 December 2015).
58. Foldvari M, Chen DW, Nafissi N, Calderon D, Narsineni L, Rafiee A. Non-viral gene therapy: gains and challenges of non-invasive administration methods. J Control Release 2015; p1130264–9.
59. Correa S, Dreaden EC, Gu L, Hammond PT. Engineering nanolayered particles for modular drug delivery. J Control Release 2016. doi:10.1016/j.jconrel.2016.01.040.
60. Kundu SK, Sharma AR, Lee S-S, Sharma G, Doss CGP, Yagihara S, et al. Recent trends of polymer mediated liposomal gene delivery system. BioMed Res Int 2014; 2014: 934605.
61. Ndeboko B, Lemamy GJ, Nielsen PE, Cova L. Therapeutic potential of cell penetrating peptides (CPPs) and cationic polymers for chronic hepatitis B. Int J Mol Sci 2015; 16: 28230–41.
62. Altman S. The RNA–protein world. RNA 2013; 19: 589–90.
63. Miele E, Spinelli GP, Miele E, Fabrizio ED, Ferretti E, Tomao S, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine 2012; 7: 3637–57.
64. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806–11.
65. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–8.
66. Dornseifer S, Willkomm S, Far RK, Liebschwager J, Beltsiou F, Frank K, et al. RNAi revised – target mRNA-dependent enhancement of gene silencing. Nucleic Acids Res 2015; 43: 10623–32.
67. Lee JM, Yoon TJ, Cho YS. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed Res Int 2013; 2013: 782041.
68. Roskams T, Libbrecht L, Van Damme B, Desmet V. Fas and Fas ligand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritumoural cells? J Pathol 2000; 191: 150–3.
69. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347–51.
70. Watts JK, Corey DR. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic. J Pathol 2012; 226: 365–79.
71. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77: 225–31.
72. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, et al. RNA interference therapy lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011; 183: 531–8.
73. Astor TL. RNA interference, RSV and lung transplantation – a promising future for siRNA therapeutics. Am J Respir Crit Care Med 2011; 183: 427–8.
74. Almeida ML, Reis RM, Calin GA. MicroRNa history: discovery, recent applications, and next frontiers. Mutat Res Fund Mol Mech Mutagen 2011; 717: 1–8.
75. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172–87.
76. Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, et al. In vitro antiviral activity and preclinical and clinical resistance profile of Miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Antimicrob Agents Chemother 2015; 59: 599–608.
77. Lorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143–59.
78. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99: 15524–9.
79. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human onco-gene. Nature 2005; 435: 828–33.
80. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103: 7024–9.
81. Jin D, Lee H. A computational approach to identifying gene-microRNA modules in cancer. PLoS Comput Biol 2015; 11: e1004042.
82. Bader AG. miR-34 – a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.
83. Yu HW, Cho WC. The emerging role of miRNAs in combined cancer therapy. Expert Opin Biol Ther 2015; 15: 923–5.
84. Luna JM, Scheel TKH, Danino T, Shaw KS, Mele A, Fak JJ, et al. Hepatitis C virus RNA functionally sequesters miR-122. Cell 2015; 160: 1099–110.
85. Jopling C, Schütz S, Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008; 4: 77–85.
86. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685–94.
87. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med 2014; 6: 851–64.
88. Rossi M, Amodio N, Di Martino MT, Tagliaferri P, Tassone P, Cho WC. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol 2014; 15: 459–67.
89. Chen H, Lan HY, Roukos DH, Cho WC. Application of microRNAs in diabetes mellitus. J Endocrinol 2014; 222: R1–R10.
90. Lee JW, Kim HJ, Heo K. Therapeutic aptamers: developmental potential as anticancer drugs. BMB Rep 2015; 48: 234–7.
91. Germer K, Leonard M, Zhang X. RNA aptamers and their therapeutic and diagnostic applications. Int J Biochem Mol Biol 2013; 4: 27–40.
92. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368–71.
93. Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann N Y Acad Sci 2006; 1082: 151–71.
94. Duda DG, Kozin V, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL 12 (SDF1 alpha)- CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 2011; 8: 2074–80.
95. Rull A, Camps J, Alonso-Villaverde C, Joven J. Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. Mediators Inflamm 2010; 2010: 326580.
96. Hoffmann S, Hoos J, Klussmann S, Vonhoff S. RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation. Curr Protoc Nucleic Acid Chem 2011; 46: 1–30.
97. Vater A, Klussmann S. Turning mirror-image oligonucleotides into drugs: the evolution of spiegelmer therapeutics. Drug Discov Today 2015; 1: 147–55.
98. Becker RC, Chan MY. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. Curr Opin Mol Ther 2009; 11: 707–15.
99. Povsic TJ, Cohen MG, Mehran R, Buller CE, Bode C, Cornel JH, et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. Am Heart J 2011; 161: 261–8.
100. Abera G, Berhanu G, Tekewe A. Ribozymes: nucleic acid enzymes with potential pharmaceutical applications: a review. Pharmacophore 2012; 3: 164–78.
101. Puerta-Fernández E, Romero-López C, Barroso-delJesus A, Berzal-Herranz A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol Rev 2003; 27: 75–97.
102. Weng DE, Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr Oncol Rep 2001; 3: 141–6.
103. Tong M, Schiff E, Jensen DM. Preliminary analysis of a phase II study of HEPTAZYMETM, a nuclease resistant ribozyme targeting hepatitis C virus (HCV) RNA. Hepatology 2002; 36: 360A.
104. Enuka Y, Lauriola M, Feldman ME, Sas-Chen A, Ulitsky I, Yarden Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res 2016; 44: 1370–83.
105. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol 2015; 22: 256–64.
106. Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA 2014; 20: 1829–42.
107. Hansen TB, Wiklund ED, Bramsen JB, Villadsen SB, Statham AL, Clark SJ, et al. miRNA-dependent gene silencing involving Ago2-mediated cleavage of a circular antisense RNA. EMBO J 2011; 30: 4414–22.
108. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol 2014; 32: 453–61.
109. Denzler R, Agarwal V, Stefano J, Bartel DP, Stoffel M. Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell 2014; 54: 766–76.
110. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. PLoS Genet 2010; 6: e1001233.
111. Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding of RNAs. Cancer Lett 2015; 365: 141–8.
112. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta 2015; 444: 132–6.